Mutational Analysis of β‐Catenin Gene in Japanese Ovarian Carcinomas: Frequent Mutations in Endometrioid Carcinomas

To investigate the contribution of the β‐catenin gene to the development of ovarian carcinomas, mutational analysis of exon 3 of the β‐catenin gene was conducted. We analyzed 61 primary ovarian carcinomas, consisting of 49 non‐endometrioid‐type and 12 endometrioid‐type tumors, for genetic alteration of the β‐catenin gene. Five carcinomas showed β‐catenin mutations (S37C, T41I, T41A), including 4 (33%) of 12 endometrioid‐type tumors and 1 (14%) of 7 mucinous‐type tumors. All of these mutations altered at the serine/threonine residues that are potential sites of GSK3‐β phosphorylation. We detected no carcinomas with interstitial deletion involving exon 3 of β‐catenin. Furthermore, we immunohistochemically studied 27 of the 61 ovarian carcinomas. Both nuclear and cytoplasmic β‐catenin expressions were demonstrated in 4 of the 27 ovarian carcinomas for which tissue samples were available for examination. All 4 cases exhibited mutations in exon 3 of β‐catenin, including a mucinous carcinoma. Our results suggested that β‐catenin gene mutation at potential GSK3‐β phosphorylation sites results in accumulation of β‐catenin protein within the cells and its translocation to nuclei. Accumulated β‐catenin protein may be involved in the development of endometrioid‐type ovarian carcinomas, and some mucinous‐type ovarian carcinomas.

[1]  Y. Nakamura,et al.  Allelotype of human ovarian cancer. , 1991, Cancer research.

[2]  Hans Clevers,et al.  XTcf-3 Transcription Factor Mediates β-Catenin-Induced Axis Formation in Xenopus Embryos , 1996, Cell.

[3]  P. Polakis,et al.  Regulation of intracellular beta-catenin levels by the adenomatous polyposis coli (APC) tumor-suppressor protein. , 1995, Proceedings of the National Academy of Sciences of the United States of America.

[4]  T. Tokino,et al.  Mutations of the β‐Catenin Gene in Endometrial Carcinomas , 1999, Japanese journal of cancer research : Gann.

[5]  R. Drury,et al.  International Histological Classification of Tumours , 1973 .

[6]  Y. Nakamura,et al.  Activation of the beta-catenin gene by interstitial deletions involving exon 3 in primary colorectal carcinomas without adenomatous polyposis coli mutations. , 1998, Cancer research.

[7]  S. Hirohashi,et al.  High Incidence of p53 Gene Mutation in Human Ovarian Cancer and Its Association with Nuclear Accumulation of p53 Protein and Tumor DNA Aneuploidy , 1992, Japanese journal of cancer research : Gann.

[8]  C. Raffel,et al.  Sporadic Medulloblastomas Contain Oncogenic β-Catenin Mutations , 1998 .

[9]  M. Inoue,et al.  Microsatellite instability and alterations in the HMSH2 gene in human ovarian cancer , 1995, International journal of cancer.

[10]  B. Gumbiner Signal transduction of beta-catenin. , 1995, Current opinion in cell biology.

[11]  M. Birrer,et al.  p53 and Ki-ras gene mutations in epithelial ovarian neoplasms. , 1993, Cancer research.

[12]  Bert Vogelstein,et al.  Mutational Analysis of the APC/β-Catenin/Tcf Pathway in Colorectal Cancer , 1998 .

[13]  Paul Polakis,et al.  Binding of GSK3β to the APC-β-Catenin Complex and Regulation of Complex Assembly , 1996, Science.

[14]  K. Kinzler,et al.  Constitutive Transcriptional Activation by a β-Catenin-Tcf Complex in APC−/− Colon Carcinoma , 1997, Science.

[15]  M. J. van de Vijver,et al.  Loss of heterozygosity for defined regions on chromosomes 3, 11 and 17 in carcinomas of the uterine cervix. , 1998, British Journal of Cancer.

[16]  A. Tanigami,et al.  Allelotype of breast cancer: cumulative allele losses promote tumor progression in primary breast cancer. , 1990, Cancer research.

[17]  N. Kusukawa,et al.  Agarose-based system for separation of short tandem repeat loci. , 1997, BioTechniques.

[18]  P. Polakis,et al.  The APC Protein and E-cadherin Form Similar but Independent Complexes with α-Catenin, β-Catenin, and Plakoglobin (*) , 1995, The Journal of Biological Chemistry.

[19]  Y. Nakamura,et al.  Activation of the beta-catenin gene in primary hepatocellular carcinomas by somatic alterations involving exon 3. , 1998, Cancer research.

[20]  D. Easton,et al.  Contribution of BRCA1 mutations to ovarian cancer. , 1997, The New England journal of medicine.

[21]  Paul Polakis,et al.  Stabilization of β-Catenin by Genetic Defects in Melanoma Cell Lines , 1997, Science.

[22]  K. Grzeschik,et al.  Localization of the human beta-catenin gene (CTNNB1) to 3p21: a region implicated in tumor development. , 1994, Genomics.

[23]  R. Kudo,et al.  Multiple primary malignancies in patients with gynecologic cancer , 1995, International journal of gynecological cancer : official journal of the International Gynecological Cancer Society.

[24]  J. Palacios,et al.  Mutations in the β-Catenin Gene (CTNNB1) in Endometrioid Ovarian Carcinomas , 1998 .

[25]  G. Chenevix-Trench,et al.  Frequent PTEN/MMAC mutations in endometrioid but not serous or mucinous epithelial ovarian tumors. , 1998, Cancer research.

[26]  B. Reviews,et al.  Histological Typing of Female Genital Tract Tumours , 1976 .

[27]  Michael Kühl,et al.  Functional interaction of β-catenin with the transcription factor LEF-1 , 1996, Nature.

[28]  Steven E. Bayer,et al.  A strong candidate for the breast and ovarian cancer susceptibility gene BRCA1. , 1994, Science.

[29]  S. Hirohashi,et al.  Beta-catenin mutation in carcinoma of the uterine endometrium. , 1998, Cancer research.